Lyell Immunopharma (LYEL) Return on Capital Employed Growth (1y) (2022 - 2026)
Lyell Immunopharma (LYEL) Return on Capital Employed Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | -3,457.00 |
| 10 | Lyell Immunopharma | 284.39 Mn | 284.39 Mn | - | 293.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293.00 |
| Dec 31, 2025 | -1,142.00 |
| Sep 30, 2025 | -5,799.00 |
| Jun 30, 2025 | -6,099.00 |
| Mar 31, 2025 | -5,124.00 |
| Dec 31, 2024 | -3,810.00 |
| Sep 30, 2024 | -1,007.00 |
| Jun 30, 2024 | -961.00 |
| Mar 31, 2024 | -1,418.00 |
| Dec 31, 2023 | -1,315.00 |
| Sep 30, 2023 | -275.00 |
| Jun 30, 2023 | -514.00 |
| Mar 31, 2023 | 92.00 |
| Dec 31, 2022 | -108.00 |
| Sep 30, 2022 | -528.00 |